First-In-Man Implantation Of CARMAT SAS’s Bioprosthetic Artificial Heart

Published: Dec 20, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

PARIS--(BUSINESS WIRE)--CARMAT (Paris:ALCAR) (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart project, providing an alternative for people suffering from end-stage heart failure, announces the first implantation of its artificial heart, as part of its feasibility study and in accordance with the approvals granted by the ANSM (Agence nationale de sécurité du médicament et des produits de santé, the French health authority) and the Comité de Protection des Personnes (ethics committee).

Help employers find you! Check out all the jobs and post your resume.

Back to news